Pd08-08 time to second biochemical recurrence as a prognostic indicator in post-prostatectomy patients who undergo salvage radiation therapy: an rtog 9601 based post-hoc analysis

You have accessJournal of UrologyProstate Cancer: Localized: Radiation Therapy (PD08)1 Sep 2021PD08-08 TIME TO SECOND BIOCHEMICAL RECURRENCE AS A PROGNOSTIC INDICATOR IN POST-PROSTATECTOMY PATIENTS WHO UNDERGO SALVAGE RADIATION THERAPY: AN RTOG 9601 BASED POST-HOC ANALYSIS Emily Chan, Akshay Sood, Jacob Keeley, Nicholas Corsi, Marcus Jamil, Deepansh Dalela, Mani Menon, Craig Rogers, and Firas Abdollah Emily ChanEmily Chan More articles by this author , Akshay SoodAkshay Sood More articles by this author , Jacob KeeleyJacob Keeley More articles by this author , Nicholas CorsiNicholas Corsi More articles by this author , Marcus JamilMarcus Jamil More articles by this author , Deepansh DalelaDeepansh Dalela More articles by this author , Mani MenonMani Menon More articles by this author , Craig RogersCraig Rogers More articles by this author , and Firas AbdollahFiras Abdollah More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001976.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The prognostic significance of a ‘second’ biochemical recurrence (sBCR) after salvage radiation therapy (sRT) with/without hormonal therapy following primary radical prostatectomy in men with prostate cancer has not been examined. We hypothesized that a shorter time to sBCR will be associated with worse cancer control outcomes. METHODS: The RTOG 9601 study included 760 patients with tumor stage pT2/T3, pN0, who had either persistent PSA post-radical prostatectomy or developed subsequent biochemical recurrence with PSA levels between 0.2 and 4.0 ng/mL. All patients received sRT (with or without 2-years of Bicalutamide) from years 1998 to 2015. For our study, we focused on 421 patients who had sBCR after sRT. sBCR was defined as PSA values above 0.2 ng/mL over the first nadir. Patients were divided into two categories: early sBCR (n=210) and late sBCR (n=211) using median time to sBCR (3.5 years). All patients who experienced sBCR received salvage hormonal therapy. Time-varying Fine-Gray analysis was used to examine the impact of early vs later sBCR on prostate-cancer specific mortality (CSM), after accounting for covariates. RESULTS: The majority of patients were age 60 years or older (75.8%), had pT3 disease (74.8%), and Gleason score ³7 (75.2%). Overall, 13.8% had persistent PSA initially after surgery. At 10-year, CSM rate was 31.2% in the early sBCR group vs 20.3% in the late sBCR group (p=0.03, Figure 1). In competing-risk analysis, time to sBCR was an independent predictor of CSM, where patients with early sBCR had 1.7-fold higher CSM risk (p=0.026) than their counterparts with late sBCR. CONCLUSIONS: Time to sBCR after sRT (with or without concomitant Bicalutamide) is a significant predictor of CSM following initial radical prostatectomy. This information can be used to guide subsequent treatments, and to counsel patients. Source of Funding: N/A © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e116-e117 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Emily Chan More articles by this author Akshay Sood More articles by this author Jacob Keeley More articles by this author Nicholas Corsi More articles by this author Marcus Jamil More articles by this author Deepansh Dalela More articles by this author Mani Menon More articles by this author Craig Rogers More articles by this author Firas Abdollah More articles by this author Expand All Advertisement Loading ...